-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Follicular Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Follicular Lymphoma Drug Details: NKTR-255 is under development for the treatment of relapsed...
-
Product Insights
NewSecondary (Hypogonadotropic) Hypogonadism – Drugs In Development, 2024
Empower your strategies with our Secondary (Hypogonadotropic) Hypogonadism – Drugs In Development, 2024 report and make more profitable business decisions. Hypogonadotropic hypogonadism (HH) is a form of hypogonadism caused by a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes, like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH), and luteinizing hormone (LH). Symptoms include a lack of development at puberty, enlargement of the testes and penis, deepening of...
-
Product Insights
NewMale Hypogonadism – Drugs In Development, 2024
Empower your strategies with our Male Hypogonadism – Drugs In Development, 2024 report and make more profitable business decisions. Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass, and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles, and untreated sleep apnea. Treatment includes hormone replacement. The Male Hypogonadism drugs in development market research report provide comprehensive information...
-
Product Insights
NewNeuromyelitis Optica (Devic’s Syndrome) – Drugs In Development, 2024
Empower your strategies with our Neuromyelitis Optica (Devic's Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Neuromyelitis optica (NMO), also known as Devic's syndrome, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord, or nerves. NMO is an autoimmune condition where the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness, and bladder/bowel problems. The Neuromyelitis Optica (Devic's Syndrome) drugs in development market research report provide...
-
Product Insights
NewIdiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Drugs In Development, 2024
Empower your strategies with our Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Drugs In Development, 2024 report and make more profitable business decisions. Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose, and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on the lower legs. The Idiopathic Thrombocytopenic...
-
Product Insights
NewThrombocytopenia – Drugs In Development, 2024
Empower your strategies with our Thrombocytopenia – Drugs In Development, 2024 report and make more profitable business decisions. Thrombocytopenia refers to a lower than normal platelet count in the blood. Platelets are crucial for blood clotting and preventing bleeding. Various factors can cause thrombocytopenia, including certain medications, infections, autoimmune disorders, or conditions affecting bone marrow function. Symptoms may range from mild bruising and petechiae (small red or purple spots on the skin) to more severe bleeding in the nose, gums, or...
-
Product Insights
NewAcquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024
Empower your strategies with our Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into "warm" and "cold" types, depending on the...
-
Product Insights
NewPrimary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...
-
Product Insights
NewPeripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2024
Empower your strategies with our Peripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral T-cell lymphomas (PTCL) constitute a diverse group of rare and aggressive non-Hodgkin lymphomas originating from mature T cells. These malignancies involve lymphoid tissues and may affect organs throughout the body. PTCLs are heterogeneous, comprising various subtypes with distinct clinical behaviors and outcomes. Symptoms may include enlarged lymph nodes, fever, weight loss, and night sweats. Diagnosis involves biopsies, imaging studies,...
-
Product Insights
NewB-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024
Empower your strategies with our B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024 report and make more profitable business decisions. B-cell acute lymphocytic leukemia (B-Cell ALL), also known as B-cell acute lymphoblastic leukemia, is a type of blood cancer that originates in the bone marrow and affects B-cell lymphocytes, a type of white blood cell. In B-cell ALL, these immature B cells undergo malignant transformation, leading to the rapid production of abnormal lymphoblasts. These abnormal cells...